EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised Hosts

Hailey S Ross, Ronald H Dallas, Jose A Ferrolino, Madeline B Johnson, Kim J Allison, Shane J Cross, Randall T Hayden, Asuncion Mejias iD, Diego R Hijano iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Hailey S Ross und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Immunocompromised Host, Respiratory Syncytial Virus, Human, Respiratory Tract Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: American Lebanese Syrian-Associated Charities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric immunocompromised patients are at an increased risk of severe respiratory syncytial virus (RSV) infection. Here, we aimed to describe the clinical course and outcomes of RSV infection in immunocompromised children.

Methods

This single‐center study at St. Jude Children's Research Hospital involved immunocompromised children ≤21 years old with a positive RSV clinical test from 2007 to 2019. Demographic and clinical characteristics, laboratory values, treatment delays for underlying conditions, and outcomes were gathered from electronic medical records. Multivariate models identified risk factors predictive of severe RSV‐lower respiratory tract infection (LRTI).

Results

A total of 391 patients, predominantly children over 2 years old (median age: 5), were included in the study. Acute lymphoblastic leukemia (ALL) was the most prevalent underlying disease. Most patients (85.7%) exhibited upper respiratory tract infections, while approximately 6% progressed to LRTIs. Over half of the patients (58.8%) required hospitalization, and one‐third experienced modifications or delays in their underlying disease treatment due to RSV infection. Severe RSV infections were observed in 15.9% of patients. All‐cause mortality was 2.6%, with 0.7% of deaths attributed to RSV.

Conclusions

One‐third of patients experienced a delay in treatment for their underlying disease due to RSV infection, a phenomenon not well understood but potentially significant. Many immunocompromised children with RSV require hospitalization, including those over 2 years old. RSV imposes a significant burden on immunocompromised children of all ages, affecting their cancer treatment plans both directly and indirectly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsImmunocompromised HostRespiratory Syncytial Virus, HumanRespiratory Tract InfectionsHumansChild, PreschoolMaleFemaleChildInfantAdolescentPrognosisRisk FactorsYoung AdultRetrospective StudiesFollow-Up StudiesHospitalization

Stichwörter der Autor:innen

RSVcancerchemotherapyhematopoietic cell transplanthospitalization

Autor:innen und Institutionen

  • Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

ORCID-Profile: Asuncion Mejias, Diego R Hijano

Förderung

  • American Lebanese Syrian-Associated Charities

Zitieren

APA

Ross, H. S., Dallas, R. H., Ferrolino, J. A., Johnson, M. B., Allison, K. J., Cross, S. J., Hayden, R. T., Mejias, A., & Hijano, D. R. (2025). Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised Hosts. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31484

Vancouver

Ross HS, Dallas RH, Ferrolino JA, Johnson MB, Allison KJ, Cross SJ, et al. Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised Hosts. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31484

BibTeX
@article{Ross2025,
  author = {Ross, Hailey S and Dallas, Ronald H and Ferrolino, Jose A and Johnson, Madeline B and Allison, Kim J and Cross, Shane J and Hayden, Randall T and Mejias, Asuncion and Hijano, Diego R},
  title = {Clinical Outcomes of Respiratory Syncytial Virus Infection Among Pediatric Immunocompromised Hosts},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31484}
}
Kostenlos starten →